Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Ascending-dose, Phase II Study to Determine the Minimum Effective Dose of APD421 in the Prevention of Cisplatin-induced Nausea and Vomiting

NCT01303978 is registered in ClinicalTrials.gov with Acacia Pharma Ltd as lead sponsor.

NCT NCT01303978
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01303978 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Ascending-dose, Phase II Study to Determine the Minimum Effective Dose of APD421 in the Prevention of Cisplatin-induced Nausea and Vomiting
Lead sponsor
Acacia Pharma Ltd
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2011
Completion date
July 31, 2012
Enrollment
51 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy-induced nausea and vomiting